AXS-05 Shows Antidepressant Separation From Control by Week 1 in MDD
This pooled early-response analysis of two 6-week trials describes the onset and symptom-level profile of dextromethorphan-bupropion (AXS-05), an oral N-methyl-D-aspartate (NMDA) receptor antagonist, which pharmacists will increasingly see in major depressive disorder (MDD) treatment.
Can an investigational NMDA antagonist deliver rapid relief in depression?
AXS-05 is a novel treatment option for major depressive disorder (MDD) that shows rapid antidepressant effects. AXS-05 showed significant improvements over placebo and bupropion in depression symptoms as early as Week 1, with notable improvement in Montgomery-Åsberg Depression Rating Scale scores. While promising, AXS-05 is still investigational, and the study outcomes need to be validated across larger populations before influencing routine clinical practice. AXS-05 demonstrates rapid antidepressant effects, but further validation is necessary before clinical use.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Jones A, Streicher C, Alter S, Thomas Z, Tabuteau H
Citation:Jones A, Streicher C, Alter S, et al. Rapid Antidepressant Effects and MADRS Item Improvements With AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA Receptor Antagonist in Major Depressive Disorder: Results From Two Randomized Double-Blind, Controlled Trials. CNS spectrums. 2023;28(2):263. doi:10.1017/S1092852923002158